BIO Comments on FDA Draft Guidance on Pediatric Rare Diseases – A Collaborative Approach for Drug Development Using Gaucher Disease as a Model
February 5, 2018
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Pediatric Rare Diseases – A Collaborative Approach for Drug Development Using Gaucher Disease as a Model.
BIO appreciates the FDA’s intended goal with the guidance – to reduce the total number of children needed for enrollment in clinical studies – and applauds the agency’s willingness to accept innovative trial designs to limit the number of patients in the control arm and thereby improve trial efficiency.
However, BIO has concerns with the guidance, particularly with the FDA’s suggestion for the use of multi-arm, multi-company clinical studies, which have inherent limitations and challenges. In the comments, BIO details these concerns and provides suggestions for clarifying and improving the guidance.
Download Full Comments Below
BIO Letter Pediatric Rare Diseases A Collaborative Approach For Drug Development Using Gaucher Disease As A Model FDA-2017-N-6476
The Biotechnology Innovation Organization appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ Information Collection Request on the Part C and Part D Medicare Prescription Payment Plan Model Documents.
In response to their advance notice of proposed rulemaking (ANPRM), BIO submitted comments to the DOJ's National Security Division on implementing the White House Executive Order of February 28, 2024, “Preventing Access to Americans’ Bulk Sensitive…
We, the undersigned, are writing to express our strong concern with a proposed update to the Medicaid Drug Rebate Program. If finalized in its current form, the proposed rule (CMS-2434-P) would impose significant costs to the government and industry…
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Pediatric Rare Diseases – A Collaborative Approach for Drug Development Using Gaucher Disease as a Model.
BIO appreciates the FDA’s intended goal with the guidance – to reduce the total number of children needed for enrollment in clinical studies – and applauds the agency’s willingness to accept innovative trial designs to limit the number of patients in the control arm and thereby improve trial efficiency.
However, BIO has concerns with the guidance, particularly with the FDA’s suggestion for the use of multi-arm, multi-company clinical studies, which have inherent limitations and challenges. In the comments, BIO details these concerns and provides suggestions for clarifying and improving the guidance.